Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection--report of five cases.

S. J. Lin, T. Y. Lin, C. H. Chiu, Y. C. Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Five cases of at-risk neonates for severe varicella infection were reported. Intravenous immunoglobulin (IVIG) was given soon after birth in different ways to four of them (Case 1 received 400 mg/kg/day for the first three days of life; Case 2 received a single dose of 200 mg/kg on day 2, and another dose of 160 mg/kg on day 7; Cases 3 and 4 received 400 mg/kg on day 2). All five patients were given acyclovir therapy, 40 to 45 mg/kg/day for five to nine days. (Case 1 for prophylaxis, Cases 2, 3, 4, 5 for treatment). Case 2, 3, 4, 5 developed vesicular rash, mild to moderate in degree, with rapid resolution without any constitutional symptoms. Case 1, who received both IVIG and acyclovir for prophylaxis, had no vesicle occurrence. IVIG, in combination with acyclovir, is a safe and probably effective regimen for preventing severe varicella in at-risk neonates. A multi-centered, collaborative study is mandatory to study the efficacy of prophylactic acyclovir with IVIG in these neonates.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalActa Paediatrica Sinica
Volume36
Issue number1
Publication statusPublished - Jan 1995
Externally publishedYes

Fingerprint

Acyclovir
Chickenpox
Intravenous Immunoglobulins
Newborn Infant
Infection
Exanthema
Parturition
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection--report of five cases. / Lin, S. J.; Lin, T. Y.; Chiu, C. H.; Huang, Y. C.

In: Acta Paediatrica Sinica, Vol. 36, No. 1, 01.1995, p. 53-57.

Research output: Contribution to journalArticle

@article{fb1070f22d614abf8f704e66ccf0df4f,
title = "Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection--report of five cases.",
abstract = "Five cases of at-risk neonates for severe varicella infection were reported. Intravenous immunoglobulin (IVIG) was given soon after birth in different ways to four of them (Case 1 received 400 mg/kg/day for the first three days of life; Case 2 received a single dose of 200 mg/kg on day 2, and another dose of 160 mg/kg on day 7; Cases 3 and 4 received 400 mg/kg on day 2). All five patients were given acyclovir therapy, 40 to 45 mg/kg/day for five to nine days. (Case 1 for prophylaxis, Cases 2, 3, 4, 5 for treatment). Case 2, 3, 4, 5 developed vesicular rash, mild to moderate in degree, with rapid resolution without any constitutional symptoms. Case 1, who received both IVIG and acyclovir for prophylaxis, had no vesicle occurrence. IVIG, in combination with acyclovir, is a safe and probably effective regimen for preventing severe varicella in at-risk neonates. A multi-centered, collaborative study is mandatory to study the efficacy of prophylactic acyclovir with IVIG in these neonates.",
author = "Lin, {S. J.} and Lin, {T. Y.} and Chiu, {C. H.} and Huang, {Y. C.}",
year = "1995",
month = "1",
language = "English",
volume = "36",
pages = "53--57",
journal = "Pediatrics and Neonatology",
issn = "1875-9572",
publisher = "臺灣兒科醫學會",
number = "1",

}

TY - JOUR

T1 - Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection--report of five cases.

AU - Lin, S. J.

AU - Lin, T. Y.

AU - Chiu, C. H.

AU - Huang, Y. C.

PY - 1995/1

Y1 - 1995/1

N2 - Five cases of at-risk neonates for severe varicella infection were reported. Intravenous immunoglobulin (IVIG) was given soon after birth in different ways to four of them (Case 1 received 400 mg/kg/day for the first three days of life; Case 2 received a single dose of 200 mg/kg on day 2, and another dose of 160 mg/kg on day 7; Cases 3 and 4 received 400 mg/kg on day 2). All five patients were given acyclovir therapy, 40 to 45 mg/kg/day for five to nine days. (Case 1 for prophylaxis, Cases 2, 3, 4, 5 for treatment). Case 2, 3, 4, 5 developed vesicular rash, mild to moderate in degree, with rapid resolution without any constitutional symptoms. Case 1, who received both IVIG and acyclovir for prophylaxis, had no vesicle occurrence. IVIG, in combination with acyclovir, is a safe and probably effective regimen for preventing severe varicella in at-risk neonates. A multi-centered, collaborative study is mandatory to study the efficacy of prophylactic acyclovir with IVIG in these neonates.

AB - Five cases of at-risk neonates for severe varicella infection were reported. Intravenous immunoglobulin (IVIG) was given soon after birth in different ways to four of them (Case 1 received 400 mg/kg/day for the first three days of life; Case 2 received a single dose of 200 mg/kg on day 2, and another dose of 160 mg/kg on day 7; Cases 3 and 4 received 400 mg/kg on day 2). All five patients were given acyclovir therapy, 40 to 45 mg/kg/day for five to nine days. (Case 1 for prophylaxis, Cases 2, 3, 4, 5 for treatment). Case 2, 3, 4, 5 developed vesicular rash, mild to moderate in degree, with rapid resolution without any constitutional symptoms. Case 1, who received both IVIG and acyclovir for prophylaxis, had no vesicle occurrence. IVIG, in combination with acyclovir, is a safe and probably effective regimen for preventing severe varicella in at-risk neonates. A multi-centered, collaborative study is mandatory to study the efficacy of prophylactic acyclovir with IVIG in these neonates.

UR - http://www.scopus.com/inward/record.url?scp=0029207076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029207076&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 53

EP - 57

JO - Pediatrics and Neonatology

JF - Pediatrics and Neonatology

SN - 1875-9572

IS - 1

ER -